NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Assembly Biosciences, Inc. ASMB
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$72.3M
▲ 153.5% vs FY2024
EPS · FY25
$-0.55
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-5.1%
Net margin · FY25
-8.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 72.3M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 8 cents on every revenue dollar this year.
Per share
USD -0.55
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-5.1%
Return on equity, FY2025
ROE
Operating margin-16.8%
Net margin-8.5%
Return on assets-3.2%
Each USD of equity lost 5 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−1.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+179.0%
Change, 10 years—
The share count grew 179% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 257.6M
total assets, end of FY2025
Total assetsUSD 257.6M
EquityUSD 206.8M
CashUSD 58.5M
Current ratio5.22×
Equity funds 80% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.1
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.55
−6.69
−13.38
−23.08
−3.00
−1.75
−3.72
−3.98
−2.41
−2.57
−1.81
−3.40
−5.00
−1.94
−3.57
−24.67
−10.02
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−5.1
−107.9
−98.9
−74.0
−63.4
−24.2
−40.4
−56.1
−44.4
−44.6
−32.1
−57.3
−91.7
−94.7
−148.8
·
·
·
·
Shares out B
0.02
0.01
0.01
0.00
0.05
0.03
0.03
0.03
0.02
0.02
0.02
0.01
0.00
0.01
0.01
0.01
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed